RxDoctor Payments Data

Austin Skakle, DO

Internal Medicine · Greensboro, NCNPI 1770938235

Payments from drug & device makers

$2,163in general payments, 2019–2025

Across 125 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$388
  • AbbVie$275
  • Sanofi-aventis U.S. LLC$150
  • Boehringer Ingelheim$117
  • Novo Nordisk$102
  • Amgen$102
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,157100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,163 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$99,725
Medicare patients
149
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$99,892
JardianceEmpagliflozin64$67,724
EliquisApixaban56$64,311
XareltoRivaroxaban44$41,004
MounjaroTirzepatide24$26,762
TradjentaLinagliptin15$24,570
TrulicityDulaglutide22$19,783
MyrbetriqMirabegron12$15,090
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,311
Lagevrio (Eua)Molnupiravir15$9,379
Tresiba Flextouch U-100Insulin Degludec22$9,065
Atorvastatin Calcium520$6,395
PaxlovidNirmatrelvir/Ritonavir24$5,482
Omeprazole191$3,660
SymbicortBudesonide/Formoterol Fumarate13$2,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$99,89261 claims
Boehringer IngelheimJardiance, Tradjenta$117$92,29579 claims
PfizerEliquis, Paxlovid$92$69,79380 claims
Lilly USA, LLCMounjaro, Trulicity$388$46,54546 claims
AstraZenecaBreztri Aerosphere, Symbicort$51$15,17827 claims
Astellas Pharma US IncMyrbetriq$88$15,09012 claims
MerckLagevrio (Eua)$13$9,37915 claims
Sanofi-aventis U.S. LLCLantus$150$78112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →